NCT05787002View on ClinicalTrials.gov

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

May 15, 2023

Study Completion Date

May 15, 2023

Conditions
Dyslipidemia
Interventions
DRUG

AZD0780

AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.

DRUG

Rosuvastatin

Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.

Trial Locations (1)

21225

Research Site, Brooklyn

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT05787002 - A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. | Biotech Hunter | Biotech Hunter